Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Neuroblastoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive 1Melanoma 1Medulloblastoma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1Astrocytoma 1

Interventions

Specimen Handling 12Magnetic Resonance Spectroscopy 12Temozolomide 11Radiotherapy 8Radiation 5Surgical Procedures, Operative 3Biopsy 3trametinib 2dabrafenib 2Spinal Puncture 2Radiotherapy, Intensity-Modulated 2Genetic Therapy 2Craniotomy 2Bevacizumab 2vorasidenib 1vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tocilizumab 1ribociclib 1pembrolizumab 1atezolizumab 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Standard of Care 1Restraint, Physical 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × Eflornithine × 90 days × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡